Compare Newmont Corporation (NEM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Revvity Inc — how do they compare? Newmont Corporation trades at $127.77 (market cap $135.62B), while Revvity Inc trades at $124.14 (market cap $13.82B). The key difference: Newmont Corporation is far larger — about 9.8× Revvity Inc's market cap, and Newmont Corporation pays the higher dividend (0.81%). Which is the better fit depends on your goals.
| NEM | RVTY | |
|---|---|---|
Market Cap | $135.62B | $13.82B |
Sector | Basic Materials | Technology |
52-Week High | $135.14 | $130.94 |
52-Week Low | $78.32 | $82.26 |
Enterprise Value | $132.21B | $16.14B |
Dividend Yield | 0.81% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEM trades at $127.09, down 0.78% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $22.67B in 2025, with net income surging to $7.09B, and Q2 2026 EPS beat expectations at $2.10. Analyst consensus is strongly bullish with a $134.63 price target, supported by record free cash flow and institutional buying.
Outlook remains positive given earnings beats and gold's safe-haven appeal, but production challenges and cost pressures pose risks. The stock offers growth from operational strength and shareholder returns, yet investors face volatility from commodity prices and execution hurdles.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
